Please ensure Javascript is enabled for purposes of website accessibility

Stock Information

Stock Quote & Chart

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Historical Price Lookup

Week of May 20, 2024

Date Requested Open Price Day High Day Low Closing Price Volume Split Adjustment Factor
May 20, 2024 $41.19 $43.29 $40.99 $43.22 884,326 1:1
May 21, 2024 $43.15 $43.29 $41.63 $42.56 1,084,601 1:1
May 22, 2024 $42.63 $43.99 $42.05 $43.60 1,259,809 1:1
May 23, 2024 $43.02 $43.13 $39.23 $39.68 1,942,977 1:1

NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investment Calculator

Initial Investment on Nov 09, 2017
Original Shares:
1,000.00
Original Value:
$14,030.00
Current Shares:
1,000.00
Current Value:
$39,680.00
Current Price:
$39.68
Split Adjustment:
1
182.82% Return

Return calculations do not include reinvested cash dividends.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Analyst Coverage

Firm Analyst
Baird
Colleen Kusy
BofA Global Research
Tazeen Ahmad
Citigroup Inc
Yigal Nochomovitz Ph.D.
Cowen and Company
Philip Nadeau Ph.D.
Evercore ISI
Umer Raffat
Goldman Sachs
Salveen Richter
H.C. Wainwright
Douglas Tsao
Jefferies
Akash Tewari
J.P. Morgan
Anupam Rama
Mizuho
Graig Suvannavejh
Needham & Co.
Joey Stringer
Oppenheimer & Co. Inc.
Francois Brisebois
Raymond James
Steven Seedhouse
Stifel
Annabel Samimy
UBS
Eliana Merle
Wedbush
Laura Chico
Wells Fargo
Derek Archila

Apellis Pharmaceuticals, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Apellis Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Apellis Pharmaceuticals, Inc. or its management. Apellis Pharmaceuticals, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.